Introducing Fosamax, its Dosage and Uses
Posted by Ronald K. Redman on Monday, September 26, 2011
Under: Fosamax Lawsuit
Fosamax or also known as Fosamax+D is the brand name of Alendronate Sodium or Alendronic Acid. The purpose of this drug is to cure bones that are weakening and deteriorating. Study suggests that response to bisphosphonates correlates with Vitamin D levels.
Merck & Co. Inc., one of the world’s pharmaceutical giant, first created and sold Fosamax. It was originally approved in September 1995. Merck’s patent expiry was in 2008 even so, it continues to sell Fosamax and now combines it with vitamin D, naming it as Fosamax+D. Today, the drug is also being produced by Barr Pharmaceuticals. Fosamax sales reached up to $3 billion in 2007 and that was just before Merck & Co. Inc. lost its patent protection. In the same year, it had been prescribed more than twenty million times.
What is Fosamax?
Fosamax or alendronate sodium is in the group of medicines called bisphosphonates. Alendronate sodium is chemically described as (4-amino-1-hydroxybutylidene) bisphosphonic acid monosodium salt trihydrate.
Alendronate sodium’s physical appearance is a white, crystalline, non-hygroscopic powder. Fosamax is practically insoluble in chloroform, very slightly soluble in alcohol, and soluble in water.
Fosamax in tablet form is free of acid and contains 6.53, 13.05, 45.68, 52.21 or 91.37mg of alendronate monosodium salt trihydrate, which is the molar equivalent of 5, 10, 35, 40 and 70 mg, respectively. The inactive ingredients of Fosamax tablets are microcrystalline cellulose, anhydrous lactose, croscarmellose sodium, and magnesium stearate. The 10mg Fosamax tablets also contain carnauba wax.
Furthermore, the oral solution of Fosamax contains 91.35 mg of alendronate monosodium salt trihydrate, which is the molar equivalent to 70 mg of free acid. Each Fosamax solution bottle also contains the following inactive ingredients: sodium citrate dihydrate and citric acid anhydrous as buffering agents, sodium saccharin, artificial raspberry flavor, and purified water. Added as preservatives are sodium propylparaben 0.0225% and sodium butylparaben 0.0075%.
When to use Fosamax?
Fosamax alters the cycle of bone formation and breakdown in the body. As stated earlier, Fosamax slows bone loss while increasing bone mass, which may prevent bone fractures.
”Resorption” is the process of reducing bone degeneration. It is the effect of Fosamax which is again a bipshosphonate drug usually prescribed for men and women with osteoporosis. Fosamax is also used to cure Paget’s disease of bone in men and women.
To treat osteoporosis, Fosamax is used to increase bone mass and reduces the possibility of fractures including the hip’s and spine’s.
Furthermore, for the prevention of osteoporosis, Fosamax may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause.
Paget’s disease is also treated by Fosamax. Bone having alkaline phosphatase at least two times the normal limit is what puts the person into the risk of getting this disease.
Fosamax may have caused you to be given Fosamax prescriptions. However, there have been news about consumers and patients filing Fosamax Lawsuits against its manufacturer. Hence, to avoid any undesirable incidents, you should consult your health care expert if you have doubts and queries about your Fosamax therapy.
Merck & Co. Inc., one of the world’s pharmaceutical giant, first created and sold Fosamax. It was originally approved in September 1995. Merck’s patent expiry was in 2008 even so, it continues to sell Fosamax and now combines it with vitamin D, naming it as Fosamax+D. Today, the drug is also being produced by Barr Pharmaceuticals. Fosamax sales reached up to $3 billion in 2007 and that was just before Merck & Co. Inc. lost its patent protection. In the same year, it had been prescribed more than twenty million times.
What is Fosamax?
Fosamax or alendronate sodium is in the group of medicines called bisphosphonates. Alendronate sodium is chemically described as (4-amino-1-hydroxybutylidene) bisphosphonic acid monosodium salt trihydrate.
Alendronate sodium’s physical appearance is a white, crystalline, non-hygroscopic powder. Fosamax is practically insoluble in chloroform, very slightly soluble in alcohol, and soluble in water.
Fosamax in tablet form is free of acid and contains 6.53, 13.05, 45.68, 52.21 or 91.37mg of alendronate monosodium salt trihydrate, which is the molar equivalent of 5, 10, 35, 40 and 70 mg, respectively. The inactive ingredients of Fosamax tablets are microcrystalline cellulose, anhydrous lactose, croscarmellose sodium, and magnesium stearate. The 10mg Fosamax tablets also contain carnauba wax.
Furthermore, the oral solution of Fosamax contains 91.35 mg of alendronate monosodium salt trihydrate, which is the molar equivalent to 70 mg of free acid. Each Fosamax solution bottle also contains the following inactive ingredients: sodium citrate dihydrate and citric acid anhydrous as buffering agents, sodium saccharin, artificial raspberry flavor, and purified water. Added as preservatives are sodium propylparaben 0.0225% and sodium butylparaben 0.0075%.
When to use Fosamax?
Fosamax alters the cycle of bone formation and breakdown in the body. As stated earlier, Fosamax slows bone loss while increasing bone mass, which may prevent bone fractures.
”Resorption” is the process of reducing bone degeneration. It is the effect of Fosamax which is again a bipshosphonate drug usually prescribed for men and women with osteoporosis. Fosamax is also used to cure Paget’s disease of bone in men and women.
To treat osteoporosis, Fosamax is used to increase bone mass and reduces the possibility of fractures including the hip’s and spine’s.
Furthermore, for the prevention of osteoporosis, Fosamax may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause.
Paget’s disease is also treated by Fosamax. Bone having alkaline phosphatase at least two times the normal limit is what puts the person into the risk of getting this disease.
Fosamax may have caused you to be given Fosamax prescriptions. However, there have been news about consumers and patients filing Fosamax Lawsuits against its manufacturer. Hence, to avoid any undesirable incidents, you should consult your health care expert if you have doubts and queries about your Fosamax therapy.
In : Fosamax Lawsuit